Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lopinavir + ritonavir + remdesivir
- Development stage
- Preclinical
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a combination of three antiviral drugs: lopinavir, ritonavir, and remdesivir. Lopinavir and ritonavir are both HIV protease inhibitors; they act by inhibiting viral proteases essential for the maturation of infectious viral particles. Ritonavir also inhibits cytochrome P450 3A4, boosting the plasma levels of lopinavir. Remdesivir is a nucleotide analog prodrug that inhibits viral RNA-dependent RNA polymerase, blocking viral RNA synthesis through delayed chain termination after incorporation into nascent viral RNA. This triple combination has been investigated for enhanced antiviral efficacy against SARS-CoV-2 in COVID-19 due to their complementary mechanisms—protease inhibition and polymerase inhibition[1][4][8].
- Brand names
- Kaletra
- Other names
- lopinavir/ritonavir/remdesivirremdesivir/lopinavir/ritonavir
02
Targets
RdRp (Coronavirus RNA-dependent RNA polymerase)CYP3A4 (Cytochrome P450 3A4)PLpro (Papain-like protease)PR (Progesterone receptor)
Beyond the preview
Go deeper on lopinavir + ritonavir + remdesivir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lopinavir + ritonavir + remdesivir.